The MedTech and HealthTech Corporate Divestiture landscape over the next 12 months

Nelson Advisors
7 minutes ago
12 min read

The global medical technology and healthcare technology sectors are undergoing a profound structural realignment, shifting from post-pandemic volume driven consolidation toward highly disciplined portfolio design. Corporate divestitures, spin-offs and carve-outs have become primary mechanisms for multinational healthtech organisations seeking to optimise operating margins, reduce debt and redeploy capital toward high-growth, high-margin clinical categories. Driven by macroeconomic volatility, persistent inflation, supply chain pressures and localised market headwinds, corporate boards are abandoning broad diversification in favour of absolute category leadership.

This corporate rationalisation is further accelerated by operational challenges in key markets such as China, alongside shifts in clinical care delivery, particularly the rapid migration of procedures to ambulatory surgical centres (ASCs) and home-care environments.

Consequently, corporate assets that fail to align with a parent company's core operating model, clinical sales channels, or capital expenditure requirements are actively being carved out.

Over the next 12 months, this structural pivot will produce a deep pipeline of high-value carve-out opportunities for both strategic acquirers and private equity investors.

The New Paradigm of Portfolio Discipline and Strategic Consolidation

The broader medtech mergers and acquisitions landscape demonstrates a clear rebound in aggregate transaction values, contrasted by a decline in overall deal participation. This divergence indicates a highly selective environment where capital is concentrated in fewer, larger, and more strategic transactions. Aggregate announced medtech deal values surged to approximately $61 Billion in 2025, up from $45 Billion in 2024 and $26 Billion in 2023. This momentum has carried into 2026, with the first half of the year generating $36.5 Billion in transaction value, including a robust Q1 that recorded approximately $27 Billion across 38 deals.

This consolidation is characterised by massive strategic platforms, illustrated by Boston Scientific's $14.5 Billion acquisition of thrombectomy leader Penumbra in January 2026 and Danaher Corporation's $9.9 Billion acquisition of Masimo Corporation in February 2026. Together, these two transactions represented approximately 94% of total Q1 2026 deal value, highlighting a market that heavily favours established, operationally mature targets with proven scalability.

Concurrently, spin-offs and divestitures accounted for approximately 34% of total medtech deal value in 2025, a noticeable increase from the five-year historical average of 29%. This acceleration reflects a fundamental shift in corporate strategy. Large multinationals are actively pruning non-core operations to unlock shareholder value and defend operating margins. Recent landmark divestitures, such as Solventum's $4.1 Billion sale of its Purification & Filtration business to Thermo Fisher Scientific and Baxter International's $3.8 Billion sale of its Vantive kidney care unit to the Carlyle Group, demonstrate how corporate spin-offs are rapidly followed by secondary portfolio rationalisation.

Major Medtech Divisional Divestitures and Structural Separations (2025–2026)

Divesting Parent	Target Business Unit / Division	Transaction Value & Structure	Buyer / Transaction Partner	Operational Status / Close Date
Becton Dickinson	Biosciences & Diagnostic Solutions	$17.5 Billion; Reverse Morris Trust	Waters Corporation	Completed February 9, 2026
Solventum	Purification & Filtration	$4.1 Billion; Direct Asset Sale	Thermo Fisher Scientific	Completed
Baxter International	Vantive Kidney Care	$3.8 Billion; Direct Asset Sale	Carlyle Group & Atmas Health	Completed January 2025
Royal Philips	Emergency Care	Undisclosed Value; Brand Licensing	Bridgefield Capital	Completed January 8, 2026
Medtronic	Patient Monitoring & Recovery (Partial)	$6.1 Billion; Cash Asset Sale	Cardinal Health	Completed

This ongoing rationalisation suggests that corporate diversification is being systematically deprioritised in favor of market-specific depth. Companies are increasingly evaluating where they possess a differentiated "right to win," shedding auxiliary businesses to concentrate financial and human capital on high-margin, clinically urgent spaces.

Active Divisional Carve-Outs and Structured Separations

The corporate carve-out pipeline for the next 12 months is anchored by several multi-billion-dollar divisions currently undergoing active financial and operational separation. These assets are transitioning from integrated corporate units into independent, market-ready targets.

Siemens Healthineers: The Diagnostics Carve-Out

The most significant structural separation in the active pipeline is the formal carve-out of the Diagnostics business unit by Siemens Healthineers. In May 2026, corporate management officially transitioned the Diagnostics separation from an exploratory assessment to an active, group-wide operational carve-out project.

This decision was driven by sharp operational divergence between the company's high-performing imaging and advanced therapies segments and its underperforming diagnostics division. The Diagnostics business has faced severe headwind in the Chinese market, which accounts for approximately 10% of total Siemens Healthineers revenue, due to the domestic implementation of volume-based procurement policies and centralised reimbursement cuts. This pricing pressure led to a 6.5% year-over-year decline in Diagnostics revenue, dragging down consolidated corporate performance and prompting management to lower its fiscal 2026 revenue growth guidance to 4.5%–5.0% and compress its adjusted basic earnings per share outlook to €2.20–€2.30.

The Diagnostics carve-out is structured to establish absolute strategic optionality. By decoupling the Diagnostics business from the highly profitable Imaging and Precision Therapy divisions, Siemens Healthineers creates a clean asset prepared for a potential trade sale, a joint venture, or a private equity buyout.

This operational separation runs parallel to a broader corporate event: parent company Siemens AG is preparing to deconsolidate its remaining 67% controlling stake in Siemens Healthineers. Siemens AG plans to execute a direct spin-off of a 30% stake in Siemens Healthineers to its own shareholders in early 2027, with formal shareholder votes scheduled for February 2027. Carving out the volatile Diagnostics segment maximises the market value and financial profile of the core Siemens Healthineers imaging business prior to this parent-level unwind.

Johnson & Johnson: The DePuy Synthes Strategic Unwind

Johnson & Johnson is actively preparing for a major portfolio rationalization through the potential sale or structured carve-out of its orthopedics subsidiary, DePuy Synthes, in a transaction estimated to exceed $20 billion. DePuy Synthes is a major force in the global orthopaedic market, producing hip, knee, trauma, and spine implants that generated approximately $9.3 billion in revenue in 2025 and maintained a 6.3% growth rate in the first quarter of 2026.

Despite its scale, the orthopedics division represents a mature, capital-intensive segment characterized by heavy clinical sales overhead and pricing compression. Johnson & Johnson's overarching strategy is to shift capital and operational focus entirely toward its highest-growth, highest-margin segments, specifically Innovative Medicine and its advanced interventional MedTech solutions in surgery, vision, and cardiovascular care.

While J&J originally evaluated a tax-free public spin-off as the primary separation path, the company has pivoted to compile comprehensive carve-out financials to facilitate a direct sale. Large-cap private equity consortiums have emerged as the most likely buyers, though interest from rival medtech strategics remains possible.

To prepare the asset for separation, DePuy Synthes has continued to execute localized acquisitions, such as its May 2026 purchase of the Gemtrack miniature radiofrequency tracking technology from MinMaxMedical. This technology integrates real-time tracking directly into DePuy's Velys digital surgery platform without relying on invasive pins or infrared line-of-sight cameras. By embedding high-value digital navigation capabilities directly into the joints portfolio, J&J is enhancing the clinical differentiation and valuation of the DePuy asset ahead of a finalised transaction.

Becton Dickinson: The Biosciences & Diagnostics Separation

The corporate separation of Becton Dickinson's (BD) Biosciences & Diagnostic Solutions business represents a completed blueprint for high-value structured carve-outs. Structured as a tax-free Reverse Morris Trust, the unit was spun off to BD shareholders and simultaneously combined with Waters Corporation in a transaction valued at $17.5 Billion. The transaction closed on February 9, 2026, following a record date set for February 5, 2026.

Under the terms of the transaction, BD received a tax-free cash distribution of $4 Billion, which the company has committed to deploying toward debt reduction and share repurchases. BD shareholders received common stock in Waters Corporation, representing a 39.2% ownership stake in the combined entity.

The resulting business combined Waters' expertise in liquid chromatography-mass spectrometry (LC-MS) and chemistry consumables with BD's diagnostic reagents, flow cytometry platforms and clinical regulatory footprint. The transaction was underpinned by highly complementary operational synergies, with the combined entity projected to realise $200 Million in annual cost synergies by year three and $290 Million in annual revenue synergies by year five. This separation allowed BD to focus on its medical and interventional segments while capturing significant equity upside in a pure-play life sciences and diagnostics leader.

The Next Wave of 12-Month Strategic Divestitures (H2 2026–H1 2027)

A secondary wave of corporate carve-outs is poised to enter the market over the next 12 months, driven by active parent restructuring, integration cleanup from recent mega-mergers, and regional risk mitigation strategies.

Medtronic: The Complete Diabetes Spin-Off and Acute Care Focus

Medtronic is actively pursuing a long-term strategy to streamline its diversified portfolio and concentrate capital on high-growth, high-margin opportunities. The primary target for complete separation in the next 12 months is its global Diabetes business unit.

The Diabetes division, while commercially scaled, has faced intense competitive pressure in the continuous glucose monitoring (CGM) and insulin pump markets, which has limited its market share expansion. In fiscal year 2025, the Diabetes segment accounted for 8% of Medtronic's consolidated revenues, but contributed only 4% of total operating profits.

To optimise its consolidated margin profile, Medtronic executed a carve-out IPO of its diabetes business under the MiniMed Group brand in Q1 2026, raising approximately $560 Million at a market capitalisation of $5.6 Billion. Medtronic plans to execute a complete split and divestiture of the remaining business by the end of 2026.

This separation follows a historical precedent of portfolio pruning at Medtronic, including the prior $6.1 billion cash sale of a portion of its Patient Monitoring & Recovery division to Cardinal Health and its renal care joint venture with DaVita.

Furthermore, Medtronic has restructured its remaining Patient Monitoring and Respiratory Interventions divisions. After canceling a planned standalone spin-off of these units in early 2024 due to shifting capital market conditions, the company combined them into a new Acute Care & Monitoring (ACM) segment. As part of this consolidation, Medtronic initiated a phase-out of its unprofitable ventilator product lines.

Sub-acute patient monitoring lines within the ACM division remain highly susceptible to secondary private equity-backed carve-outs over the next 12 months as Medtronic focuses capital on its core cardiovascular, robotic surgery, and neurovascular segments. This is demonstrated by its $550 million acquisition of Scientia Vascular to expand its neurovascular footprint.

Danaher Corporation: The Post-Acquisition Masimo Consumer Carve-Out

Danaher completed its $9.9 Billion acquisition of Masimo Corporation on June 10, 2026, integrating Masimo’s clinical pulse oximetry, brain monitoring, and acute-care automation solutions into its Diagnostics segment. The acquisition was highly strategic, expanding Danaher's diagnostics franchise alongside established operating companies such as Beckman Coulter, Radiometer, Leica Biosystems and Cepheid.

However, the final terms of the transaction required Danaher to absorb Masimo’s consumer audio and consumer health divisions, which were previously under review for a potential spin-off. Historically, Masimo’s acquisition of consumer audio parent Sound United for $1 Billion in 2022 triggered intense shareholder opposition and a proxy battle led by Politan Capital. While Masimo successfully sold Sound United to Samsung’s Harman division for $350 Million in May 2025, the remaining consumer health wearables and retail monitoring operations do not align with Danaher's business-to-business clinical model.

Danaher operates with a strict focus on highly regulated, high-margin diagnostic platforms characterised by recurring consumable revenue streams.

Consequently, Masimo’s non-clinical consumer health and retail-oriented pulse oximetry watch divisions are prime candidates for a strategic carve-out or private equity divestiture in late 2026 or early 2027 to pay down the commercial paper issued to fund the acquisition.

GE HealthCare: Targeted Localisation and Regional Carve-Outs

Since its independent spin-off from General Electric in 2023, GE HealthCare has focused on a software-enabled precision care model. In April 2026, the company executed a major segment restructuring, combining its two largest imaging divisions into a unified imaging and clinical visualization segment. This operational reorganization is designed to support its cloud-first enterprise imaging strategy, which was accelerated by the $2.3 Billion acquisition of Intelerad in March 2026.

To protect global operating margins from regional macroeconomic pressures and domestic procurement policies, GE HealthCare is pursuing highly targeted localization strategies. In January 2026, the company commenced pre-marketing activities for a carve-out sale of its localized China imaging business.

By selling a majority stake in this regional operation to domestic Chinese entities or localized joint ventures, GE HealthCare can insulate its global corporate margins from volume-based pricing compression in China. This structure allows the company to retain key manufacturing partnerships and licensing agreements while transferring capital-intensive local commercial operations off its consolidated balance sheet.

Royal Philips: Refining the Connected Care Portfolio

Royal Philips continues to execute its multi-year strategy to simplify its operational structure and concentrate resources on clinical imaging, ultrasound, and image-guided therapy. Following the completion of the sale of its Emergency Care business to Bridgefield Capital on January 8th, 2026, a transaction that included a 15 year brand licensing agreement, the company is evaluating further separations.

The company's Connected Care segment, which includes patient monitoring and sleep and respiratory care products under the Respironics brand, has faced persistent regulatory and operational headwinds. Over the next 12 months, selective carve-outs of specific sub-acute respiratory care and home-use sleep therapy product lines are highly likely. This rationalisation will enable Philips to focus capital on high-margin hospital enterprise informatics, clinical AI integrations, and coronary intravascular imaging platforms, such as its recent acquisition of SpectraWAVE.

Market Dynamics, Clinical Shifts and Valuation Adjustments

The surge in medtech carve-out activity is fundamentally linked to shifts in clinical care delivery, technological requirements, and capital market valuation resets.

Forward-Looking Pipeline of High-Probability Carve-Outs and Divestitures (H2 2026–H1 2027)

Parent Corporation	Target Divestiture / Carve-Out Unit	Estimated Valuation Range	Primary Structural Pathway	Target Market / Clinical Category	Strategic Rationale
Siemens Healthineers	Clinical Diagnostics Business	$8.0 Billion – $12.0 Billion	Group-wide formal carve-out; Trade sale or PE JV	In-Vitro Diagnostics & Core Lab Testing	Mitigate China procurement headwinds; optimize imaging core
Johnson & Johnson	DePuy Synthes	$20.0 Billion+	Direct trade sale or Private Equity buyout	Hip, Knee, Spine, and Trauma Orthopedics	Capital reallocation to innovative oncology and immunology
Medtronic	Diabetes Division (MiniMed)	$5.0 Billion – $6.0 Billion	Complete corporate split and share distribution	Insulin Pumps & CGM Systems	Enhance margins; improve agility against pure-play competitors
Danaher Corporation	Masimo Consumer Health	$400 Million – $600 Million	Secondary carve-out; Private trade sale	Wearable sensors & consumer monitoring	Focus on B2B clinical diagnostics; debt reduction
GE HealthCare	Localized China Imaging Business	TBD	Pre-marketing regional carve-out	Regional CT, MRI, and Ultrasound	Insulate global margins from local pricing pressures
Royal Philips	Connected Care / Sleep Therapy lines	$800 Million – $1.2 Billion	Selective carve-out or private asset sale	Home CPAP and Respiratory Consumables	Portfolio simplification; focus on enterprise informatics

The migration of high-acuity surgical procedures from traditional acute-care hospital settings to lower-cost, high-throughput ambulatory surgery centers (ASCs) is a primary operational catalyst. The Centers for Medicare and Medicaid Services (CMS) 2026 Hospital Outpatient Prospective Payment System and ASC Payment System final rule added more than 500 procedures to the ASC Covered Procedures List, including AFib-treating cardiac catheter ablations, advanced spine procedures, and complex cardiology interventions.

This regulatory shift has altered the commercial landscape.

Heavy, capital-intensive hardware platforms designed exclusively for stationary hospital operating rooms are experiencing declining commercial demand, making them key targets for corporate divestiture.

Conversely, procedural platforms that are mobile, digitally integrated, and optimised for rapid clinical throughput are commanding high valuation premiums.

Furthermore, the rise of GLP-1 receptor agonist therapies is reshaping strategic planning across the medtech sector. These metabolic therapies have the potential to reduce long-term device utilisation across obesity-linked therapeutic segments, including sleep apnea, diabetes management, joint reconstruction, and cardiovascular support.

In response, strategic buyers are focusing their acquisition pipelines on clinical assets that remain insulated from or complementary to GLP-1 treatment pathways. This is illustrated by Stryker's acquisition of Inari Medical, which anchors portfolio growth in late-stage thromboembolic disease that persists downstream of metabolic dysfunction. Consequently, legacy device lines that are highly vulnerable to GLP-1-driven demand declines are being systematically deprioritized and prepared for divestiture.

To bridge valuation gaps in an environment characterized by elevated capital costs and selective buyers, deal structures have evolved. Upfront cash considerations are frequently supplemented by earnouts, structured equity components, and performance-based milestone payments. These milestone payments are tied to specific clinical, regulatory, or commercial achievements, allowing sellers to capture fair value while mitigating integration risks for strategic and private equity buyers.

Strategic Conclusions - MedTech and HealthTech Corporate Divestiture in the next 12 months

The medtech and healthtech corporate divestiture landscape over the next 12 months is defined by a rigorous focus on core business optimisation and structural efficiency.

Corporate leaders are increasingly utilising carve-outs to simplify governance, reduce operational complexity and insulate corporate balance sheets from inflationary and geopolitical headwinds.

The active separation of Siemens Healthineers' diagnostics division, the potential sale of Johnson & Johnson's DePuy Synthes unit, and the ongoing spin-off of Medtronic's diabetes segment highlight a clear industry trend. These transactions demonstrate a shift away from the diversified healthcare conglomerate model in favour of agile, pure-play market leaders.

For private equity sponsors and strategic buyers, these corporate separations provide a valuable pipeline of scaled, operationally mature assets with stable cash flows and established commercial channels.

Acquirers who can successfully navigate the complexities of transitional services agreements (TSAs) and implement targeted operational improvements will be well-positioned to drive substantial value creation in a reorganising global healthcare market.

Concurrently, divesting parent corporations will emerge as more focused, agile, and high-margin entities, with the capital flexibility required to invest in next-generation digital, robotic, and precision care platforms.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech